Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Navtemadlin and its role in the treatment of R/R myelofibrosis

Srdan Verstovsek • 22 Jun 2022
EHA 2022
Myelofibrosis Myeloproliferative Neoplasms Navtemadlin Ruxolitinib
BOREAS

Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some updates on navtemadlin, an MDM2 inhibitor, for the treatment of myelofibrosis (MF). Dr Verstovsek first highlights the potential role of nevtemadlin in relapsed/refractory (R/R) disease, and then goes on to discuss the Phase III BOREAS study (NCT03662126), which is evaluating the use of this agent versus best available therapy in patients with MF who progress after JAK inhibitor therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Srdan Verstovsek

1:52
An update on the use of navtemadlin in myelofibrosis
Srdan Verstovsek • 7 Dec 2022
2:19
Insights into the Phase IIa Mylox-1 trial: assessing efficacy of GB2064 in myelofibrosis
Srdan Verstovsek • 7 Dec 2022
2:19
FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangement
Srdan Verstovsek • 7 Dec 2022
1:56
Rationale for VERIFY: rusfertide added to ongoing therapy in patients with polycythemia vera
Srdan Verstovsek • 7 Dec 2022

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals